NCT00212797已完成2 期
Prospective, Double-Blind, Randomized, Placebo-Controlled Dose Finding Study of the Efficacy and Safety of 2 Target Doses of Org 34517 Used as Adjunctive Therapy in Subjects With Psychotic Major Depression (Major Depressive Episode, Severe, With Psychotic Features).
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 273
- 主要终点
- PANSS positive symptoms subscale.
研究概览
简要总结
The primary purpose of this study is to determine whether subjects with psychotic major depression benefit from adjunctive treatment with Org 34517. Two doses of Org 34517 will be compared to placebo in this international multicenter study. The duration of this trial is 6 weeks.
详细描述
Major depression with psychotic features (psychotic depression) is the most debilitating disorder in the depressive disorders spectrum. It is associated with severe symptoms, prolonged course, poorer response rates, more residual symptoms, more frequent relapses and higher mortality, as compared to major depressive disorder.
The markedly abnormal HPA axis functioning in psychotic depression has encouraged research to investigate whether the HPA axis would be a target for pharmacotherapy in depression.
The primary purpose of this study is to determine whether subjects with psychotic major depression benefit from adjunctive treatment with GR antagonist Org 34517. Two doses of Org 34517 will be compared to placebo in this international multicenter study. The duration of this trial is 6 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •have provided voluntary written informed consent for trial participation after the scope and nature of the investigation were explained to them, and before starting any trial-related activities (before Screening);
- •be able to speak, read, understand, respond to questions, and follow
- •instructions in English or their native language;
- •have DSM-IV severe depressive episode with psychotic features, as
- •diagnosed by the MINI for single or recurrent episodes (296.24 or 296.34);
- •have a score on PANSS item "Delusions" AND/OR "Hallucinatory behavior" of at least 4 at Screening and Baseline;
- •have a PANSS Positive Scale score of at least 16 at Screening and Baseline;
- •have a total score of at least 18 on the HAMD 17-item scale at Screening and Baseline;
- •be on a stable dose of "usual treatment", which had to consist of an
- •antidepressant, an antipsychotic, a mood stabilizer or any combination of these 3 drug classes;
- •be between 18 and 75 years of age (inclusive) at Screening;
- •be willing to be hospitalized for at least 11 days from Screening onwards.
排除标准
- •have any other current psychiatric diagnosis (according to the MINI) except MDD, such as organic mental syndromes and disorders, delirium or anxiety disorders;
- •have a lifetime psychiatric diagnosis of psychotic disorders (according to the MINI), or a MINI diagnosis of past manic episode;
- •be at significant risk of committing suicide, as indicated by a score greater than 9 on the revised InterSePT Scale for Suicidal Thinking (ISST);
- •be currently treated with carbamazepine or valproate;
- •be currently treated with midazolam;
- •be treated with electroconvulsive therapy in the current episode;
- •be currently treated with more than one antidepressant;
- •be currently treated with more than one antipsychotic;
- •be currently treated with more than one mood stabilizer;
- •have a "usual treatment" started or discontinued in the 2 weeks before
- •Randomization;
- •have a "usual treatment" dose change within the week prior to
- •Randomization;
- •have any clinically unstable or uncontrollable renal, hepatic, respiratory,
- •hematological, cardiovascular or cerebrovascular disease that would put the patient at risk of safety or bias assessment of efficacy;
- •have known hypersensitivity reactions to glucocorticoid antagonists;
- •have any clinically significant abnormal laboratory data (e.g. aspartate amino transferase (ASAT) and/or alanine amino transferase (ALAT) values > 2x normal range upper limit) or ECG results, or a clinically significant abnormal outcome at the physical examination at the screening visit;
- •have any untreated or uncompensated clinically significant endocrine
- •have a MINI diagnosis of alcohol and/or drug dependence;
- •have a confirmed positive result on the drug screening test for any illicit drug, except cannabis, at Screening;
- •be using hormone replacement therapy at Screening;
- •have required concomitant treatment with corticosteroids, like
- •dexamethasone, prednisone or cortisol (topical use is allowed);
- •be diagnosed with Cushing's disease;
- •be women of childbearing potential without adequate contraception;
- •be women with a positive pregnancy test at Screening or Baseline, or
- •breastfeeding mothers;
- •be males with a current diagnosis of prostate hypertrophia or past history (less than 3 months) of symptoms of prostate hypertrophia.
- •be currently treated with clozapine (per Amendment III);
- •be currently treated with systemic or topical ketaconazole.
研究组 & 干预措施
Org 34517_1
Experimental
low dose Org 34517
干预措施: Org 34517 (Drug)
Org 34517_2
Experimental
high dose Org 34517
干预措施: Org 34517 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
PANSS positive symptoms subscale.
时间窗: 6 weeks
次要结局
- Ham-D17, CGI, Cognition, spermatogenesis(6 weeks)
研究者
相似试验
已完成
2 期
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)Major Depressive DisorderNCT01318434Euthymics BioScience, Inc.342
已完成
2 期
Dose-finding Study With Lu AA24530 in Major Depressive DisorderMajor Depressive DisorderNCT00599911H. Lundbeck A/S652
已完成
不适用
Efficacy of Psychotherapy for Depressed Parkinson's Disease PatientsParkinson's DiseaseDepressionNCT02552836Hopital Montfort63
终止
2 期
Cannabidiol as an Adjunctive Treatment for Bipolar DepressionBipolar DepressionBipolar Affective DisorderBipolar DisorderNCT03310593Hospital de Clinicas de Porto Alegre36
暂停
不适用
Selenium as Augmentation Treatment for Sertraline Resistant Major DepressionMajor DepressionNCT02890212University of Sao Paulo General Hospital60